Joost Gribnau
Joost Gribnau studied Biochemistry at Leiden University and obtained his PhD in 1999 at the Department of Cell Biology at Erasmus University Rotterdam. He completed his postdoctoral training at the Massachusetts Institute of Technology (Whitehead Institute) and started his own research group in the Department of Cell Biology at Erasmus MC, later moving to the Department of Reproduction and Development. In 2012, he was appointed Professor of Epigenetics, and in 2014 became chair of the Department of Developmental Biology at Erasmus MC. In 2019, he co-founded Methylomics B.V., a company developing diagnostic tests for cancer detection based on cancer-associated DNA methylation changes. In 2026 he moved to the LUMC as chair of the department of Cell and Chemical Biology. Joost Gribnau received several prestigious grants, including VIDI, VICI, and ERC awards, as well as the Huygens-Descartes Prize. In 2015, he was elected a member of the European Molecular Biology Organization (EMBO), and is currently a principal investigator at the Leiden node of the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW).
Publications
-
HCFC1 and YY1 coordinate COMPASS and Integrator recruitment to control X chromosome inactivation and gene regulation.
Boeren J*, Tan B*, Luchsinger-Morcelle S, Merzouk S, Rentmeester E, van Haperen R, Maduro C, Rietdijk R, Göynük B, Juksar J, van Ijcken W, Demmers JAA, Gontan M, Mira-Bontenbal H, Gribnau J.
bioRxiv 2026
-
. In vivo single cell state tracing exposes differentiation as a bidirectional process characterized by transient lineage exploration
Gonzalez Sanchez E, Fabro F, Vroeg in de Wei G, Klavert J, Boers J, Tan B, Sacchetti A, van Leeuwen M, Bindels E, Boers R, Gribnau J and Creyghton M
bioRxiv 2026
-
Genome-wide cell-free DNA methylation profiling in advanced stage ovarian cancer. Are we looking at the tumor or the patient's immune response to the tumor?
van den Berg CB, Nieuwenhuyzen-de Boer GM, Boere IA, Boers RG, Boers JB, van-IJcken WFJ, Jansen MPHM, Kirmizitas TS, Gribnau JH, van Beekhuizen HJ
Cancer Treat Res Commun. 2025
Groups:
Gribnau lab
